Health Care & Life Sciences » Biotechnology | Galectin Therapeutics Inc.

Galectin Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
10,495.00
29,134.00
25,852.00
15,368.00
3,059.00
8,253
Other Current Assets
192.00
527.00
548.00
426.00
760.00
579
Total Current Assets
10,687.00
29,661.00
26,400.00
15,794.00
3,819.00
8,832
Net Property, Plant & Equipment
3.00
1.00
-
-
-
-
Intangible Assets
23.00
15.00
8.00
1.00
-
-
Other Assets
-
-
-
-
342.00
174
Total Assets
10,713.00
29,677.00
26,408.00
15,795.00
4,161.00
9,006
Accounts Payable
762.00
-
-
-
608.00
Other Current Liabilities
1,724.00
1,703.00
1,360.00
3,780.00
2,360.00
Total Current Liabilities
2,486.00
1,703.00
1,360.00
3,780.00
2,968.00
Total Liabilities
2,486.00
1,703.00
1,360.00
3,780.00
2,968.00
Common Equity (Total)
894.00
20,628.00
17,483.00
3,053.00
7,769.00
Total Shareholders' Equity
8,227.00
27,974.00
25,048.00
12,015.00
1,193.00
Total Equity
8,227.00
27,974.00
25,048.00
12,015.00
1,193.00
Liabilities & Shareholders' Equity
10,713.00
29,677.00
26,408.00
15,795.00
4,161.00
Preferred Stock (Carrying Value)
7,333.00
7,346.00
7,565.00
8,962.00
8,962.00

About Galectin Therapeutics

View Profile
Address
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
United States
Employees -
Website http://www.galectintherapeutics.com
Updated 07/08/2019
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.